148 related articles for article (PubMed ID: 33568941)
21. The Adenosine A1 Receptor Antagonist DPCPX Inhibits Tumor Progression via the ERK/JNK Pathway in Renal Cell Carcinoma.
Zhou Y; Tong L; Chu X; Deng F; Tang J; Tang Y; Dai Y
Cell Physiol Biochem; 2017; 43(2):733-742. PubMed ID: 28950257
[TBL] [Abstract][Full Text] [Related]
22. Aspirin restores ABT-737-mediated apoptosis in human renal carcinoma cells.
Ou YC; Li JR; Wang JD; Chen WY; Kuan YH; Yang CP; Liao SL; Lu HC; Chen CJ
Biochem Biophys Res Commun; 2018 Jul; 502(2):187-193. PubMed ID: 29792865
[TBL] [Abstract][Full Text] [Related]
23. Knockdown of BAG3 sensitizes bladder cancer cells to treatment with the BH3 mimetic ABT-737.
Mani J; Antonietti P; Rakel S; Blaheta R; Bartsch G; Haferkamp A; Kögel D
World J Urol; 2016 Feb; 34(2):197-205. PubMed ID: 26100943
[TBL] [Abstract][Full Text] [Related]
24. Pan-Bcl-2 inhibitor obatoclax delays cell cycle progression and blocks migration of colorectal cancer cells.
Koehler BC; Scherr AL; Lorenz S; Elssner C; Kautz N; Welte S; Jaeger D; Urbanik T; Schulze-Bergkamen H
PLoS One; 2014; 9(9):e106571. PubMed ID: 25192188
[TBL] [Abstract][Full Text] [Related]
25. TW-37, a small-molecule inhibitor of Bcl-2, mediates S-phase cell cycle arrest and suppresses head and neck tumor angiogenesis.
Ashimori N; Zeitlin BD; Zhang Z; Warner K; Turkienicz IM; Spalding AC; Teknos TN; Wang S; Nör JE
Mol Cancer Ther; 2009 Apr; 8(4):893-903. PubMed ID: 19372562
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of NANOG/NANOGP8 downregulates MCL-1 in colorectal cancer cells and enhances the therapeutic efficacy of BH3 mimetics.
Mattoo AR; Zhang J; Espinoza LA; Jessup JM
Clin Cancer Res; 2014 Nov; 20(21):5446-55. PubMed ID: 25208882
[TBL] [Abstract][Full Text] [Related]
27. Comparison of putative BH3 mimetics AT-101, HA14-1, sabutoclax and TW-37 with ABT-737 in platelets.
Wei H; Harper MT
Platelets; 2021 Jan; 32(1):105-112. PubMed ID: 32079453
[TBL] [Abstract][Full Text] [Related]
28. Sorafenib potentiates ABT-737-induced apoptosis in human oral cancer cells.
Kim LH; Shin JA; Jang B; Yang IH; Won DH; Jeong JH; Chung TH; Cho NP; Cho SD
Arch Oral Biol; 2017 Jan; 73():1-6. PubMed ID: 27632413
[TBL] [Abstract][Full Text] [Related]
29. Synergistic induction of apoptosis by the Bcl-2 inhibitor ABT-737 and imatinib mesylate in gastrointestinal stromal tumor cells.
Reynoso D; Nolden LK; Yang D; Dumont SN; Conley AP; Dumont AG; Zhou K; Duensing A; Trent JC
Mol Oncol; 2011 Feb; 5(1):93-104. PubMed ID: 21115411
[TBL] [Abstract][Full Text] [Related]
30. Chemotherapeutic drugs sensitize human renal cell carcinoma cells to ABT-737 by a mechanism involving the Noxa-dependent inactivation of Mcl-1 or A1.
Zall H; Weber A; Besch R; Zantl N; Häcker G
Mol Cancer; 2010 Jun; 9():164. PubMed ID: 20576107
[TBL] [Abstract][Full Text] [Related]
31. Knockdown of ALPK2 blocks development and progression of renal cell carcinoma.
Jiang J; Han P; Qian J; Zhang S; Wang S; Cao Q; Shao P
Exp Cell Res; 2020 Jul; 392(2):112029. PubMed ID: 32330508
[TBL] [Abstract][Full Text] [Related]
32. Synergistic activity of fenretinide and the Bcl-2 family protein inhibitor ABT-737 against human neuroblastoma.
Fang H; Harned TM; Kalous O; Maldonado V; DeClerck YA; Reynolds CP
Clin Cancer Res; 2011 Nov; 17(22):7093-104. PubMed ID: 21933888
[TBL] [Abstract][Full Text] [Related]
33. Combination of ABT-737 and resveratrol enhances DNA damage and apoptosis in human T-cell acute lymphoblastic leukemia MOLT-4 cells.
Opydo-Chanek M; Rak A; Cierniak A; Mazur L
Toxicol In Vitro; 2017 Aug; 42():38-46. PubMed ID: 28366708
[TBL] [Abstract][Full Text] [Related]
34. B cell lymphoma-2 (BCL-2) homology domain 3 (BH3) mimetics demonstrate differential activities dependent upon the functional repertoire of pro- and anti-apoptotic BCL-2 family proteins.
Renault TT; Elkholi R; Bharti A; Chipuk JE
J Biol Chem; 2014 Sep; 289(38):26481-26491. PubMed ID: 25096574
[TBL] [Abstract][Full Text] [Related]
35. BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells.
Huang S; Sinicrope FA
Cancer Res; 2008 Apr; 68(8):2944-51. PubMed ID: 18413764
[TBL] [Abstract][Full Text] [Related]
36. Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263 to Induce Apoptosis Specifically in p53-Defective Cancer Cells.
Li X; Li B; Ni Z; Zhou P; Wang B; He J; Xiong H; Yang F; Wu Y; Lyu X; Zhang Y; Zeng Y; Lian J; He F
Mol Cancer Ther; 2017 Sep; 16(9):1806-1818. PubMed ID: 28533436
[TBL] [Abstract][Full Text] [Related]
37. Apigenin sensitizes colon cancer cells to antitumor activity of ABT-263.
Shao H; Jing K; Mahmoud E; Huang H; Fang X; Yu C
Mol Cancer Ther; 2013 Dec; 12(12):2640-50. PubMed ID: 24126433
[TBL] [Abstract][Full Text] [Related]
38. The novel BH3 α-helix mimetic JY-1-106 induces apoptosis in a subset of cancer cells (lung cancer, colon cancer and mesothelioma) by disrupting Bcl-xL and Mcl-1 protein-protein interactions with Bak.
Cao X; Yap JL; Newell-Rogers MK; Peddaboina C; Jiang W; Papaconstantinou HT; Jupitor D; Rai A; Jung KY; Tubin RP; Yu W; Vanommeslaeghe K; Wilder PT; MacKerell AD; Fletcher S; Smythe RW
Mol Cancer; 2013 May; 12(1):42. PubMed ID: 23680104
[TBL] [Abstract][Full Text] [Related]
39. Polydatin exerts anti-tumor effects against renal cell carcinoma cells via induction of caspase-dependent apoptosis and inhibition of the PI3K/Akt pathway.
Jin YL; Xin LM; Zhou CC; Ren Y
Onco Targets Ther; 2018; 11():8185-8195. PubMed ID: 30532558
[TBL] [Abstract][Full Text] [Related]
40. Telmisartan-Induced Cytotoxicity via G
Tsujiya Y; Hasegawa A; Yamamori M; Okamura N
Biol Pharm Bull; 2021; 44(12):1878-1885. PubMed ID: 34853271
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
